Jens-Kristian Jensen

The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

Laurence Klotz, L Boccon-Gibod, Neal D. Shore et al. · British Journal of Urology · 2008 · 614 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer

E. David Crawford, Bertrand Tombal, Kurt Miller et al. · The Journal of Urology · 2011 · 153 citations

Medicine, Oncology, Pharmacology +16

Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics

Bertrand Tombal, Kurt Miller, L Boccon-Gibod et al. · European Urology · 2009 · 147 citations

Medicine, Oncology, Pharmacology +8

Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer

Hendrik Van Poppel, Bertrand Tombal, Jean J. de la Rosette et al. · European Urology · 2008 · 126 citations

Medicine, Endocrinology, Pharmacology +17

A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America

Marc Gittelman, Peter Pommerville, Bo‐Eric Persson et al. · The Journal of Urology · 2008 · 104 citations

Medicine, Pharmacology, Pharmacotherapy +8